Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus OH precision instruments (NYSE: MTD) Q4 2024 revenue $1.045B (+12%), adjusted EPS $12.41 (+32%); global market leader lab balances and food inspection, pharma/biopharma lab destocking recovery competing with Sartorius.
Mettler-Toledo International Inc. is a Columbus, Ohio-based precision instruments and services company — publicly traded on the New York Stock Exchange (NYSE: MTD) as an S&P 500 Health Care component — manufacturing and marketing the world's most comprehensive range of weighing instruments and precision analytical measurement devices for laboratory, industrial, and food retail applications through approximately 18,000 employees in 40 countries. Mettler-Toledo's product portfolio spans laboratory balances and analytical instruments (used in pharmaceutical R&D and quality control), industrial scales and process analytics (used in chemical, food, and beverage manufacturing), pharmaceutical inspection systems (tablet and capsule inspection lines), food inspection equipment (X-ray and metal detection systems, checkweighers), and retail weighing solutions (supermarket scales). In Q4 2024, Mettler-Toledo reported revenue of $1.045 billion (+12% year-over-year) and adjusted EPS of $12.41 (+32% over the prior-year $9.40) — demonstrating the company's operational leverage as volume returned following the laboratory instruments market's destocking correction. CEO Patrick Kaltenbach has led Mettler-Toledo since 2020, maintaining the company's premium pricing strategy and capital return program (no dividend; all free cash flow directed to share repurchases that have reduced the share count by approximately 50% over the past decade). Mettler-Toledo operates as a category leader in precision weighing with 30%+ global market share and consistently achieves operating margins of 28-30%.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.